Invesco S&P MidCap 400® GARP ETF

Greenleaf Trust Reduced Holdings in Kinsale Capital Group by 85.6%

TD Cowen Raises RenaissanceRe's Target Price to $280

PineStone Asset Management Reduced Its Stake in Medpace

Swedbank AB Reduces Stake in Medpace Holdings

RenaissanceRe Holdings Ltd. extends credit line with Citibank Europe plc

XTX Topco Ltd Large Reduction in Medpace Holdings Shares

Medpace Holdings CEO Announces Sale of Common Stock

Medpace CEO Sells Company Shares

Medpace Holdings EVP Susan E. Burwig Reports Sale of Common Stock

Medpace Holdings Hits New 52-Week High and Reports Strong Quarterly Earnings

AppFolio CFO Reports on Common Stock Disposition

Medpace CEO August J. Troendle Disposes of Common Stock

Medpace VP Files Form 144 to Prepare for Sale of 20,000 Restricted Shares

Jefferies analyst maintains Lantheus buy rating with target price of $105

Lantheus to present new data on florbetaben F 18 at CTAD

Empirical Finance LLC Increased Holdings in Medpace Holdings in Q2

Medpace insiders sold $18,376,705 worth of shares

William Blair Analyst Reiterates Buy Rating on AppFolio

AppFolio CEO William Shane Trigg Sells Company Shares

Ozark Bank Reports Q3 2025 Financial Metrics

Rich Sparkle

Novabay Pharmac

Valens Semiconductor

Greenpower Motor

Alpha Tech

Offerpad Solutions

VCI Global

Tryhard

Tradr 2X Long APLD Daily ETF

ZeZentalis Pharma

TechnipFMC plc has secured a significant integrated Engineering, Procurement, Construction, and Installation (iEPCI™) contract from bp for the Tiber development in the Gulf of America, valued between $600 million and $800 million. This contract will be included in the company's inbound orders for Q4 2025 and follows ongoing work for bp’s Kaskida project, awarded in 2024.

Reuters

TechnipFMC

TechnipFMC Wins $600–800 Million iEPCI Contract for bp’s Tiber Project

SKYE

HALO

Skye Bioscience Inc. has signed a Non-exclusive Collaboration and License Agreement with Halozyme, Inc. for the use of Halozyme’s ENHANZE® drug delivery technology. The agreement includes milestone and royalty payments, with Halozyme supplying clinical and commercial rHuPH20 bulk drug product. This collaboration aims to develop a subcutaneous formulation of nimacimab.

Skye Bioscience

Halozyme Therap

Skye Bioscience Signs Collaboration and License Agreement with Halozyme

TechnipFMC plc has secured a substantial EPCI contract from Eni S.p.A. for the Coral North FLNG project offshore Mozambique. The contract, valued between $250 million and $500 million, involves manufacturing and installing flexible flowlines, risers, subsea manifolds, and umbilicals. This project is the second FLNG development in the region and is included in TechnipFMC's inbound orders for Q2 2025.

TechnipFMC Wins Substantial Subsea Contract for Coral North FLNG Project Offshore Mozambique

KNSL

Gregory M. Share, Director of Kinsale Capital Group Inc., reported the acquisition of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

Kinsale Capital

Director Gregory M. Share Reports Acquisition of Kinsale Capital Group Inc. Common Shares

TechnipFMC has secured a substantial contract from Chevron, valued between $75 million and $250 million, for Subsea 2.0® production systems in the Gorgon Stage 3 project. This includes 7-inch subsea trees and flexible jumpers to boost production rates and ensure flow assurance for gas applications, continuing their collaboration on the Gorgon development.

TechnipFMC Wins Significant Subsea Production Systems Contract for Chevron’s Gorgon Stage 3

TechnipFMC has secured a significant contract from Ithaca Energy to supply flexible risers for the Captain development in the U.K. North Sea. The contract, valued between $75 million and $250 million, involves designing, manufacturing, and installing risers, flowlines, and hardware. This is part of the Captain field's technology enhancements, including a second phase of enhanced oil recovery in 2024.

TechnipFMC wins significant flexible pipe contract from Ithaca Energy

Dec 4 (Reuters) - Halozyme Therapeutics Inc:HALOZYME WINS PRELIMINARY INJUNCTION AGAINST MERCK’S KEYTRUDA SC IN GERMANYHALOZYME THERAPEUTICS: AS CONSEQUENCE OF INJUNCTION MERCK’S LAUNCH ACTIVITIES FOR KEYTRUDA SC IN GERMANY WITHIN SCOPE OF ORDER MUST BE HALTEDHALOZYME THERAPEUTICS: OUTCOME OF THE INFRINGEMENT LAWSUIT AGAINST MERCK WILL NOT IMPACT ENHANZEHALOZYME THERAPEUTICS INC - IV VERSION OF KEYTRUDA REMAINS AVAILABLE TO PATIENTS Source text: Further company coverage:

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC In Germany

EWBC

Prudential Financial Inc. reduced its stake in East West Bancorp by 58.6% in Q2. Other investors adjusted their positions, with US Bancorp DE increasing its stake by 880.7%. Insiders sold shares, impacting stock ownership. East West Bancorp's stock opened at $107.15, with a market cap of $14.74 billion. Analysts expect an EPS of 8.85 for the year, with new price targets set by Citigroup and Barclays.

Market Beat

US Bancorp

Prudential financial

East West Bancorp

East West Bancorp, Inc. $EWBC Shares Sold by Prudential Financial Inc.

Halozyme Therapeutics has completed its acquisition of Elektrofi for up to $900 million. The deal includes an upfront payment of $750 million and up to $150 million in milestone payments. Halozyme expects royalty revenue from 2030 and anticipates $55 million in incremental operating expenses for 2026. Two of Elektrofi’s programs are projected to enter clinical development by 2026, with potential milestone payments of up to $275 million.

Halozyme Completes Acquisition of Elektrofi for Up to $900 Million

MRUS

Merus and Halozyme have entered a worldwide non-exclusive partnership and license agreement for the subcutaneous formulation of petosemtamab. The collaboration involves using Halozyme's Enhanze technology to enhance the delivery of petosemtamab, an EGFR x LGR5 bispecific antibody. Halozyme will receive upfront fees, milestone payments, and royalties. The partnership aims to improve treatment options for various cancers, including head and neck cancer. Both companies express optimism about the potential benefits for patients and healthcare providers.

Pharmaceutical Technology

Merus BV

Merus and Halozyme link on subcutaneous petosemtamab

TechnipFMC has secured a substantial iEPCI contract from Eni SpA for the Maha project in Indonesia, valued between $250 million and $500 million. The project involves designing and installing subsea systems and marks Eni's first use of TechnipFMC's Subsea 2.0 technology in Indonesia. This contract is part of TechnipFMC's orders for Q2 2025.

TechnipFMC Wins Substantial iEPCI Contract for Eni Maha Project in Indonesia

SCGLY

Peregrine Energy Solutions has secured funding for a $317 million battery energy storage project under construction. The financing includes a preferred equity commitment from Bildmore Clean Energy and loans from First Citizens Bank, Societe Generale, Siemens Financial Services, and East West Bank. Peregrine, founded in 2022, has developed a pipeline of 15 GWh of storage, with two projects currently under construction in Texas. This marks Peregrine's second project financing this year, highlighting continued support from investors and lenders.

prnewswire

Société Générale

17:22 ET
			
			
				Peregrine Energy Solutions Secures Funding to support a $317 Million Battery Energy Storage Project Currently Under Construction

LB filings

East West Bancorp | 10-Q: FY2025 Q3 Revenue: USD 1.23 B

Shares of Halozyme Therapeutics fell 1.1% to $67.67 following a $1.3 billion convertible bonds sale. The biopharma company raised $650 million in 0% convertible bonds due 2031 and another $650 million in 0.875% bonds due 2032, with an initial conversion price set at $87.20. The proceeds will be used for working capital, capital expenditures, potential acquisitions, and debt paydown. Additionally, Johnson & Johnson received FDA approval for a drug co-formulated with Halozyme's technology to treat high-risk smoldering multiple myeloma. Halozyme shares are up 41% year-to-date.

BUZZ-Halozyme Therapeutics down after $1.3 bln convertible bonds sale

TechnipFMC (FTI) is a leading supplier in the energy sector, recently reaching a 10-year high in share price. It holds a 100% 'Buy' opinion from Barchart, supported by strong fundamentals, projected revenue and earnings growth, and a modest dividend yield. Analysts are bullish, with multiple 'Strong Buy' ratings and optimistic price targets. FTI's market cap is $17.03 billion, and it operates in Subsea and Surface Technologies. The stock has gained 58.62% over the past year, with a current price of $41.86 and a technical support level around $41.29.

Talkmarkets

TechnipFMC - A Top Supplier To The Energy Industry

Invesco S&P MidCap 400® GARP ETF(GRPM.US)

TechnipFMC Wins $600–800 Million iEPCI Contract for bp’s Tiber Project

Skye Bioscience Signs Collaboration and License Agreement with Halozyme

TechnipFMC Wins Substantial Subsea Contract for Coral North FLNG Project Offshore Mozambique

Director Gregory M. Share Reports Acquisition of Kinsale Capital Group Inc. Common Shares

TechnipFMC Wins Significant Subsea Production Systems Contract for Chevron’s Gorgon Stage 3